• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    4/23/24 12:31:13 PM ET
    $ABEO
    $ANL
    $BIMI
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABEO alert in real time by email

    Gainers

    • VolitionRX (AMEX:VNRX) shares rose 33.6% to $0.8 during Tuesday's regular session. The market value of their outstanding shares is at $65.7 million.
    • Palisade Bio (NASDAQ:PALI) stock increased by 29.81% to $6.4. The company's market cap stands at $5.4 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares increased by 24.67% to $0.14. The market value of their outstanding shares is at $5.5 million.
    • Protagenic Therapeutics (NASDAQ:PTIX) shares increased by 23.88% to $1.55. The company's market cap stands at $6.8 million.
    • BIMI Intl Medical (NASDAQ:BIMI) stock moved upwards by 23.21% to $1.38. The market value of their outstanding shares is at $19.3 million.
    • NKGen Biotech (NASDAQ:NKGN) shares moved upwards by 20.4% to $1.77. The company's market cap stands at $40.3 million.

    Losers

    • Abeona Therapeutics (NASDAQ:ABEO) shares decreased by 52.3% to $3.51 during Tuesday's regular session. The company's market cap stands at $96.0 million.
    • Rezolute (NASDAQ:RZLT) stock decreased by 16.97% to $2.94. The market value of their outstanding shares is at $117.9 million.
    • Jaguar Health (NASDAQ:JAGX) stock decreased by 13.57% to $0.16. The company's market cap stands at $44.6 million.
    • Adlai Nortye (NASDAQ:ANL) stock declined by 13.25% to $12.51. The market value of their outstanding shares is at $461.6 million.
    • Sunshine Biopharma (NASDAQ:SBFM) shares decreased by 12.74% to $1.26. The market value of their outstanding shares is at $1.2 million.
    • Portage Biotech (NASDAQ:PRTG) stock fell 12.49% to $0.26. The company's market cap stands at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO
    $ANL
    $BIMI
    $JAGX

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Adlai Nortye Ltd.
    $ANL
    2/13/2026$16.00Neutral → Buy
    H.C. Wainwright
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    Adlai Nortye Ltd.
    $ANL
    6/2/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ABEO
    $ANL
    $BIMI
    $JAGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026

    SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced upcoming oral and poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders ("AD/PD™ 2026"), taking place March 17-21, 2026, in Copenhagen, Denmark and virtually. The presentations will highlight a new integrated analysis of patient-level data from two previously completed Phase 1 studies evaluating troculeucel in patients with

    3/10/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABEO
    $ANL
    $BIMI
    $JAGX
    SEC Filings

    View All

    SEC Form PRE 14A filed by Jaguar Health Inc.

    PRE 14A - Jaguar Health, Inc. (0001585608) (Filer)

    3/13/26 4:59:50 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-3 filed by Adlai Nortye Ltd.

    F-3 - Adlai Nortye Ltd. (0001944552) (Filer)

    3/10/26 8:47:00 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sunshine Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    3/9/26 4:05:28 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $ANL
    $BIMI
    $JAGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adlai Nortye Ltd. upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Adlai Nortye Ltd. from Neutral to Buy and set a new price target of $16.00

    2/13/26 9:51:23 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABEO
    $ANL
    $BIMI
    $JAGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Micek John was granted 7,377 shares, increasing direct ownership by 13,919% to 7,430 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    3/12/26 3:03:56 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth covered exercise/tax liability with 11,439 shares, decreasing direct ownership by 4% to 296,913 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:18:04 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron covered exercise/tax liability with 11,438 shares, decreasing direct ownership by 3% to 404,462 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:16:14 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $ANL
    $BIMI
    $JAGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $ANL
    $BIMI
    $JAGX
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABEO
    $ANL
    $BIMI
    $JAGX
    Financials

    Live finance-specific insights

    View All

    Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

    CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will b

    3/3/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

    Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI). The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self

    12/11/25 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

    - First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success - - $207.5M in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2025 expected to fund operations for over two years - CLEVELAND, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results and business highlights for the third quarter of 2025 and shared recent operational progress. "We are scaling the ZEVASKYN launch to meet patient needs

    11/12/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $ANL
    $BIMI
    $JAGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Protagenic Therapeutics Inc.

    SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)

    11/14/24 5:19:32 PM ET
    $PTIX
    Biotechnology: Pharmaceutical Preparations
    Health Care